RxDoctor Payments Data

Ashley Kirby Ware

Family · Prentiss, MSNPI 1912258450

Payments from drug & device makers

What this record shows

This record is dominated by other: $14,000 of the $14,508 with a category attached, or 96.5%. Skye Orthobiologics LLC accounts for 96.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $14,024 and has fallen 98.6% since, to $190 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,508in general payments, 2019–2025

Across 18 payments — averaging $806.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Skye Orthobiologics LLC$14K
  • Johnson & Johnson$150
  • Alkermes, Inc.$80
  • AbbVie$75
  • Indivior Inc.$74
  • Boehringer Ingelheim$64
  • plus $65 from 2 others

What the payments were for

  • Food & beverage$5084%
  • Other$14,00096%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,508 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$14,014
Medicare patients
50
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$32,538
JardianceEmpagliflozin17$14,405
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,884
JanumetSitagliptin Phos/Metformin Hcl14$6,178
Albuterol Sulfate HfaAlbuterol Sulfate52$1,571
Gabapentin67$635
Potassium Chloride43$459
Pantoprazole Sodium55$354
Famotidine23$344
Losartan Potassium61$297
Amlodipine Besylate122$294
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide47$294
Levothyroxine Sodium47$280
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$256
Metoprolol Succinate24$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$64$14,40517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Prentiss

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →